Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells
about
Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patientsFunctional Role of the microRNA-200 Family in Breast Morphogenesis and NeoplasiaBuilding bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell aciniDistinctive properties of metastasis-initiating cellsSystematic functional perturbations uncover a prognostic genetic network driving human breast cancerProtein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.Conserved modular domains team up to latch-open active protein kinase CαThe three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevanceExpression of miR-34c induces G2/M cell cycle arrest in breast cancer cellsDistinct EMT programs control normal mammary stem cells and tumour-initiating cells.Chromatinized protein kinase C-θ directly regulates inducible genes in epithelial to mesenchymal transition and breast cancer stem cellsDefinition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancerMicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasisCDK7-dependent transcriptional addiction in triple-negative breast cancer.Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.Tackling the cancer stem cells - what challenges do they pose?Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition.Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expressionA breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages.Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer.Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.Protein kinase Cα mediates erlotinib resistance in lung cancer cells.XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine.Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.Classifying ten types of major cancers based on reverse phase protein array profiles.The pluripotency factor NANOG promotes the formation of squamous cell carcinomasMZF-1/Elk-1 Complex Binds to Protein Kinase Cα Promoter and Is Involved in Hepatocellular Carcinoma.Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells.EGFR Signal-Network Reconstruction Demonstrates Metabolic Crosstalk in EMT.UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.ERK5 negatively regulates tobacco smoke-induced pulmonary epithelial-mesenchymal transition.IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.DAG/PKCδ and IP3/Ca²⁺/CaMK IIβ Operate in Parallel to Each Other in PLCγ1-Driven Cell Proliferation and Migration of Human Gastric Adenocarcinoma Cells, through Akt/mTOR/S6 Pathway.PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival.p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
P2860
Q54907456-008C3156-12B4-4A2C-B92F-7FD36A683527Q54907457-EED34E69-3157-41F7-81AF-245BBF47FBDCQ54907458-A82AF1FF-7502-462E-BEB1-AB4521EC4414Q54907459-ABC67613-B444-49E1-9752-061364C8331CQ54907460-7F16FE1E-4360-4F7F-851E-E7D12FD2E49DQ54907461-5E1AE3E6-0380-4E68-9696-E088852E851FQ54907462-C6EF757E-C04B-4500-9F48-1ABC88D402C6Q54907463-B0F7B23C-D22D-47A5-A17D-240FF6ADC662Q54907467-6EF5A2BC-049B-49DF-B397-5BE11D35F8CBQ54907468-E1808712-DBD2-4903-B511-BA61B292B099Q54907470-13D535A7-B3D3-4C09-8118-25A04D9B3D2D
P1343
Q26858812-3AE04230-486C-47C5-80E0-4C6A022ACBCFQ26861636-4ED6C08D-9BA1-4163-B7BD-0EB4C1A95795Q27317149-BD200356-7A70-42E0-B62D-78851B2EEB62Q28069801-5C067303-5456-4F17-87F0-E7DADEC2CDA2Q33591245-DE33C980-24B1-4B4E-8F84-7CBA2CE2C3F0Q33700622-FE9D8DF0-4B98-4668-AA8A-82ECE74BFE2BQ33793028-6999EE02-EA3C-47A6-93FB-C0C21DF36700Q33903662-95261306-EF55-409D-A6CB-E5C054D374F7Q33975619-B08DC4CE-23F2-4951-8F4D-103CD4AFB629Q34017850-2BFDD9E6-DEF3-42F4-8B23-611B4C46B939Q34044818-06289236-F40D-4452-A927-EB1119EC6662Q34056549-2A37443C-8742-4F58-93FD-46F301B4DE3BQ34135362-A392C9CD-7445-41CD-9D2E-7431BAE2CF41Q34260220-AD791888-2474-4F2E-B653-9B6187E0FA63Q34495729-A7DB097B-F039-49D1-9C11-8714503CF26DQ34516879-D1B5331F-87DA-484A-8A40-9FEFA6AD050AQ34523263-4EFC01A7-5A58-449B-BBA4-8325D716999CQ34601999-2B61AA0B-00ED-42A2-8F19-C677B3E6AB54Q34924229-8504EC56-8803-4D6C-B2CF-0B520B2DD297Q34975953-085C302C-800A-4C43-AAD4-70B49182E662Q35000293-D5367C89-7E14-45BD-B4DA-F15AF7A206D3Q35067924-CC4A4C33-6DDD-42A5-B70B-9440CFD94594Q35128358-061C22BC-CB37-456A-8847-336F16D82F18Q35154337-A37F97EF-9FE5-4CB6-B0D0-8B32FF32E9BFQ35356072-D51239FD-3ACD-4F29-B042-E7A9747093E7Q35531840-BF263FDF-6C6A-48B3-B54F-D9C6BD7DE7C5Q35533034-0532AC2E-AAE2-47DD-B8A2-A9EC5144A983Q35545078-3650C8A6-4A2F-4F45-8271-225C1A210B32Q35590038-C4274902-9762-47CF-A13A-A593A98EEE14Q35623354-9C6BE000-297D-41FF-9822-13AA4CDA4D89Q35641350-71402645-C8A6-4471-AA3B-39B29E9C04ABQ35890322-2613514E-2869-459D-AB67-AC1A63508C3DQ36037821-50262887-1401-44BA-806C-166172895B41Q36048547-6F0A6467-CDAB-419E-821A-C70DFD9F02AAQ36260600-A9597A87-F471-417A-BABB-3CC02A2666B9Q36266768-F9DE0BEC-C01A-4BF3-868B-8A9CD28B871BQ36404038-7BE9C02B-A207-4758-80D4-DB5232FBDF9AQ36437097-C165548F-09C9-43BB-9E7F-24F826DBB00AQ36685360-DAA7A606-8C08-4F9C-BB63-8D09F050B8D7Q36687990-692C3F49-9A58-479E-A8ED-24E0AF45101D
P2860
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Protein kinase C α is a centra ...... t for breast cancer stem cells
@ast
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en-gb
Protein kinase C α is a centra ...... t for breast cancer stem cells
@nl
type
label
Protein kinase C α is a centra ...... t for breast cancer stem cells
@ast
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en-gb
Protein kinase C α is a centra ...... t for breast cancer stem cells
@nl
prefLabel
Protein kinase C α is a centra ...... t for breast cancer stem cells
@ast
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en-gb
Protein kinase C α is a centra ...... t for breast cancer stem cells
@nl
P2093
P2860
P4510
P50
P3181
P1433
P1476
Protein kinase C α is a centra ...... t for breast cancer stem cells
@en
P2093
Boon Seng Soh
Jordan A Krall
Joyce Buikhuisen
Wenjun Guo
Zhenhua Jeremy Wu
P2860
P304
P3181
P356
10.1016/J.CCR.2013.08.005
P407
P50
P577
2013-09-09T00:00:00Z